Literature DB >> 565680

Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with cis- and trans-diamminedichloroplatinum(II).

L A Zwelling, K W Kohn, W E Ross, R A Ewig, T Anderson.   

Abstract

cis- and trans-diamminedichloroplatinum(II) (PDD) produced a DNA cross-linking effect in mouse leukemia L1210 cells, which was demonstrable after subtoxic treatments with the DNA alkaline elution technique. Cross-linking effects developed following treatments with concentrations as low as 1 micron for cis-PDD and 5 micron for trans-PDD, which permitted over 80% survival of colony-forming ability. The maximum cross-linking effect by cis-PDD required about 12 hr of posttreatment incubation before it was fully developed, whereas the cross-linking effect of trans-PDD was fully developed at the end of the 1-hr drug exposure. The cross-linking effects of both agents were reversed upon further incubation of the cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 565680

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  mus308 mutants of Drosophila exhibit hypersensitivity to DNA cross-linking agents and are defective in a deoxyribonuclease.

Authors:  J B Boyd; K Sakaguchi; P V Harris
Journal:  Genetics       Date:  1990-08       Impact factor: 4.562

2.  Unwinding of supercoiled DNA by cis- and trans-diamminedichloroplatinum(II): influence of the torsional strain on DNA unwinding.

Authors:  W M Scovell; F Collart
Journal:  Nucleic Acids Res       Date:  1985-04-25       Impact factor: 16.971

Review 3.  A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP.

Authors:  B J Foster; B J Harding; M K Wolpert-DeFilippes; L Y Rubinstein; K Clagett-Carr; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  [Cis-diamminedichloroplatinum(II). A new antineoplastic agent derived from the group of heavy metal complexes (author's transl)].

Authors:  R Osieka; C G Schmidt
Journal:  Klin Wochenschr       Date:  1979-12-03

5.  Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum (II).

Authors:  A L Pinto; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

6.  Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.

Authors:  M C Poirier; S J Lippard; L A Zwelling; H M Ushay; D Kerrigan; C C Thill; R M Santella; D Grunberger; S H Yuspa
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

7.  Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.

Authors:  S A Holden; B A Teicher; M F Robinson; D Northey; A Rosowsky
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Response of murine erythroleukemia cells to cis- and trans-diamminedichloroplatinum (II).

Authors:  T S Vates; G L Brake; S K Majumdar; G L Ferguson
Journal:  In Vitro Cell Dev Biol       Date:  1986-06

9.  Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.

Authors:  S E Brooks; T T Korbut; N P Dupuis; S A Holden; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Cytogenetic toxicity of antitumor platinum compounds in Fanconi's anemia.

Authors:  E H Poll; F Arwert; H Joenje; A W Eriksson
Journal:  Hum Genet       Date:  1982       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.